Crossmark

miR-451a levels rather than human papillomavirus vaccine administration is associated with the severity of murine experimental autoimmune encephalomyelitis

Crossref DOI link: https://doi.org/10.1038/s41598-021-88842-z

Published Online: 2021-04-30

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nakashima, Momoka

Ishikawa, Kana

Fugiwara, Aika

Shu, Kaiin

Fukushima, Yoshimi

Okamoto, Masaaki

Tsukamoto, Hirotake

Kouwaki, Takahisa

Oshiumi, Hiroyuki
Funding

Funding for this research was provided by:

AMED

MEXT
License Information

Text and Data Mining valid from 2021-04-30

Version of Record valid from 2021-04-30
More Information

Article History

Received: 25 September 2020

Accepted: 16 April 2021

First Online: 30 April 2021

Competing interests

: A patent related to this work has been submitted. H.O. and K.I. are the inventors, and the applicant is Kumamoto University. Application numbers for the patent are TOKUGAN2018-15968 (Japan) and PCT/JP2019/33742 and cover miR-451a as a biomarker to predict onset and severity of autoimmune diseases. The patent is currently pending. The authors have no other competing interests.

Document is current

Any future updates will be listed below